feedback

Course Director

Leonard H. Calabrese, DO
Leonard H. Calabrese, DO

Cleveland Clinic Lerner
RJ Fasenmyer
Case Western Reserve University
Cleveland, Ohio

Faculty

Evan J. Lipson
Evan J. Lipson, MD

Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CNE
Credit Amount:1.0 Credits
Release Date:2019-Mar-29
Expiration Date:2020-Mar-28
Estimated Time for Completion:1 hour
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they’re used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies.

Upon completion of this activity, participants will be able to:
  • Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies
  • Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy
  • Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation
  • Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs
  • Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology
  • Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology

Target Audience

This activity has been designed to meet the educational needs of rheumatologists, rheumatology nurses, physician assistants, and other clinicians involved in the management of immune-related rheumatic and other adverse events induced by immune checkpoint inhibitors used in the treatment of cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 29, 2019 - March 28, 2020
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

Course Director and Moderator

Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
RJ Fasenmyer Chair of Clinical Immunology
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Cleveland, Ohio

Leonard H. Calabrese, DO, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb; Crescendo Bioscience, Inc.; Genentech, Inc.; Gilead ; Horizon Pharma plc.; Janssen Pharmaceuticals, Inc.; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Bristol-Myers Squibb; Crescendo Bioscience, Inc.; Genentech, Inc.; Horizon Pharma plc.; Janssen Pharmaceuticals, Inc.; and UCB, Inc.

Leonard H. Calabrese, DO, does intend to include either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies, combinations, and agents for management of irAEs.

Discussant

Evan J. Lipson, MD
Associate Professor, Medical Oncology
Melanoma and Cancer Immunology Programs
Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan J. Lipson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for MacroGenics, Inc.
Grant/Research Support from Bristol-Myers Squibb; Merck & Co., Inc.; and Sysmex.
Advisory Board for Array BioPharma; Bristol-Myers Squibb; EMD Serono, Inc.; Merck & Co., Inc.; Millennium; and Novartis Pharmaceuticals Corporation.

Evan J. Lipson, MD, does intend to include either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies, combinations, and agents for management of irAEs.

Content Reviewers

Matthew A. Goodman, MD, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Amita B. Patel, MSN, RN, AOCNP, NP-C, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Kristin Tomlinson, PhD
PVI, PeerView Institute for Medical Education

Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

Providership


This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through an educational grant from Bristol-Myers Squibb.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.